Jin CB, Yang L. Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases. World J Clin Cases 2021; 9(18): 4617-4626 [PMID: 34222428 DOI: 10.12998/wjcc.v9.i18.4617]
Corresponding Author of This Article
Ling Yang, MD, Chief Doctor, Department of Thoracic Oncology, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Wuhan 430000, Hubei Province, China. 348711624@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2021; 9(18): 4617-4626 Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4617
Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
Cai-Bao Jin, Ling Yang
Cai-Bao Jin, Ling Yang, Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan 430000, Hubei Province, China
Author contributions: Jin CB performed the research and wrote the paper; Yang L supervised the report.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Hubei Cancer Hospital.
Informed consent statement: Written informed consent was waived.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling Yang, MD, Chief Doctor, Department of Thoracic Oncology, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Wuhan 430000, Hubei Province, China. 348711624@qq.com
Received: January 26, 2021 Peer-review started: January 26, 2021 First decision: February 25, 2021 Revised: March 11, 2021 Accepted: April 12, 2021 Article in press: April 12, 2021 Published online: June 26, 2021 Processing time: 135 Days and 18.4 Hours
Core Tip
Core Tip: We retrospectively diagnosed nine cases of non-small cell lung cancer (SCLC) transforming to SCLC, large-cell neuroendocrine carcinoma, or squamous cell carcinoma on re-biopsy after epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Tumor re-biopsy should be performed routinely when EGFR-TKI therapy fails in lung cancer patients to avoid ignoring histological transformation and to select a subsequent therapeutic strategy. The plasma pro-gastrin-releasing peptide and NSE levels could be valuable and significant biomarkers to predict histological transformation. The transformed tumor retained the original EGFR mutation, which indicates that histological transformation represents an evolution from the initial tumor.
